FDA Approves First Factor XIa Inhibitor for Secondary Stroke Prevention

Approval is for use with antiplatelet therapy in adults with noncardioembolic ischemic stroke or high-risk transient ischemic attack
pill senior
Adobe Stock
Published on: 
Updated on: 
Loading content, please wait...